Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit? - Lipides Nutrition Cancer - UMR866 Accéder directement au contenu
Article Dans Une Revue Cancer Medicine Année : 2021

Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Résumé

INTRODUCTION: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population?MATERIALS AND METHODS: Patients were identified from the three French hematological malignancies population-based registries. All CML patients (ICD-O-3: 9875/3) diagnosed between 2006 and 2016 and resided in registries areas were included. The TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis. An alluvial plot described the pathways leading to death.RESULTS: In total, 507 CML patients received TKI in first-line treatment, 22% were enrolled in a clinical trial. After adjustment, NG-TKI patients were significantly more likely to achieve MMR during first-line therapy than IM patients (HR: 1.88 CI95% [1.35-2.61]). At the end of follow-up, 212 patients were still in first-line therapy (46 of them died), 203 switched to second-line (43 subsequently died), 26 were on TFR from first-line (4 subsequently died), and 20 stopped their treatment (16 subsequently died).DISCUSSION: In this comprehensive real-life setting, the results were consistent with clinical trials. The results are not sufficient to conclude that a NG-TKI treatment is superior with regard to these patients, despite indications regarding differences between the TKI generation effect on survival and tolerance.
Fichier principal
Vignette du fichier
BPH_CM_2021_Canet.pdf (644.46 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03440252 , version 1 (22-11-2021)

Licence

Paternité

Identifiants

Citer

Jim Canet, Pascale Cony-Makhoul, Sebastien Orazio, Edouard Cornet, Xavier Troussard, et al.. Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?. Cancer Medicine, 2021, 10 (20), pp.6959-6970. ⟨10.1002/cam4.4186⟩. ⟨hal-03440252⟩
24 Consultations
20 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More